New pill combo aims to tame hard-to-treat bone marrow cancer
Disease control
Recruiting now
This early-stage study tests an oral combination of tetrahydrouridine and decitabine in 20 adults with myelodysplastic syndromes (MDS) that relapsed or didn't respond to prior therapy. Participants take the drug once a week for 24 weeks and visit the clinic monthly. The main goal…
Phase: PHASE1 • Sponsor: Treebough Therapies • Aim: Disease control
Last updated May 15, 2026 11:56 UTC